TrialsgrambetaRCTs are beautiful

VOYAGER PAD

2020

Vascular Outcomes Study of ASA Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD

In 6,564 patients with peripheral artery disease after lower-extremity revascularisation, rivaroxaban 2.5 mg twice daily plus aspirin reduced acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke or cardiovascular death compared with aspirin alone.

Result

Efficacy: Composite of acute limb ischaemia, major amputation, MI, ischaemic stroke or CV deathHR 0.85 (95% CI 0.76-0.96) · P = 0.009

Safety: ISTH major bleedingHR 1.42 (95% CI 1.10-1.84)

Below 1 favours rivaroxaban 2.5 mg twice daily plus aspirin, above 1 favours aspirin alone.

Event rates Rivaroxaban 2.5 mg twice daily plus aspirin 17.3% vs aspirin alone 19.9% (composite of acute limb ischaemia, major amputation, MI, ischaemic stroke or CV death)

Original publication
Subtopic
Antithrombotic therapy
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Bonaca MP, Bauersachs RM, et al. N Engl J Med. 2020;382(21):1994-2004.doi 10.1056/NEJMoa2000052

Discussion & critique

The benefit is driven largely by acute limb ischaemia while major bleeding rises significantly, so selection by bleeding risk is essential. It is the only positive antithrombotic trial in the post-revascularisation PAD population and anchors dual-pathway inhibition in the guideline.

Discussed in podcasts